Author

Javier Gisbert

IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Javier Gisbert  et al.

CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Javier Gisbert  et al.

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

Javier Gisbert  et al.

ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
TRENDS IN THE PRESCRIPTION OF EMPIRICAL TREATMENTS AND THEIR EFFECTIVENESS IN NAÏVE PATIENTS OVER 10 YEARS (2013-2022) IN EUROPE: DATA FROM THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Javier Gisbert  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

Javier Gisbert  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

Javier Gisbert  et al.

ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAÏVE PATIENTS IN THE PERIOD 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)

Javier Gisbert  et al.

RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY
RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY

Javier Gisbert  et al.

EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2020: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)
FIRST-LINE EMPIRICAL H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 30,000 CASES OF THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

Item 61 - 78 / 78
1 2 3
4